Skip to content

Study · Not a test of the peptide alone · 2019

6 results

Prosocial effects of an oxytocin metabolite, but not synthetic oxytocin receptor agonists, in a mouse model of autism.

Moy SS, Teng BL, Nikolova VD, Riddick NV, Simpson CD, Van Deusen A, Janzen WP, Sassano MF, Pedersen CA, Jarstfer MB

Neuropharmacology3 Nov 2018Cited by 21 (Europe PMC)

PMID30399367 (opens in a new tab)PMCIDPMC7384330 (opens in a new tab)DOI10.1016/j.neuropharm.2018.10.036 (opens in a new tab)PepBankPUB-30399367
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 01AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome

    In the BALB/cByJ mouse model of ASD-like social deficits, the oxytocin metabolite OT(4-9) produced significant social preference in a dose-dependent manner.

    In plain wordsIn mice with autism-like social deficits, a fragment of oxytocin called OT(4-9) increased social preference in a dose-dependent way.

    Peptide
    Oxytocin
    Outcome
    IncreaseSocial preference after OT(4-9)
    Study

    mousen: not reported in source

    BALB/cByJ mouse model of ASD-like social deficits
    Outcome group
    Social behavior and cognition · Nervous system and cognition

    Source sentences

    Summary
    While OT(5-9) failed to affect social deficits, the metabolite OT(4-9) led to significant social preference in the BALB/cByJ model, in a dose-dependent manner.
    1 context sentence
    Summary · context
    We first investigated two synthetic oxytocin analogs, TC-OT-39 and carbetocin, using in vitro cell-based assays for pharmacological characterization and behavioral tests in the BALB/cByJ mouse model of ASD-like social deficits.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  2. 02AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome

    In the BALB/cByJ mouse model, increased sociability with the oxytocin metabolite OT(4-9) (2.0 mg/kg) was seen at both 24 h and 12 days after the end of a subchronic regimen.

    In plain wordsIn mice with autism-like social deficits, social behaviour stayed higher 24 hours and 12 days after a course of the oxytocin fragment OT(4-9).

    Peptide
    Oxytocin
    Outcome
    IncreaseSociability at 24 h and 12 days after OT(4-9) regimen
    Study

    mousen: not reported in source

    BALB/cByJ mouse model of ASD-like social deficits
    Outcome group
    Social behavior and cognition · Nervous system and cognition

    Source sentences

    Summary
    The increased sociability was observed at both 24 h and 12 days following the end of a subchronic regimen with OT(4-9) (2.0 mg/kg).
    1 context sentence
    Summary · context
    We first investigated two synthetic oxytocin analogs, TC-OT-39 and carbetocin, using in vitro cell-based assays for pharmacological characterization and behavioral tests in the BALB/cByJ mouse model of ASD-like social deficits.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  3. 03AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome

    In the BALB/cByJ mouse model, the oxytocin metabolite OT(5-9) failed to affect social deficits.

    In plain wordsIn mice with autism-like social deficits, the oxytocin fragment OT(5-9) did not change social deficits.

    Peptide
    Oxytocin
    Outcome
    No significant changeSocial deficits after OT(5-9)
    Study

    mousen: not reported in source

    BALB/cByJ mouse model of ASD-like social deficits
    Outcome group
    Social behavior and cognition · Nervous system and cognition

    Source sentences

    Summary
    While OT(5-9) failed to affect social deficits
    1 context sentence
    Summary · context
    We first investigated two synthetic oxytocin analogs, TC-OT-39 and carbetocin, using in vitro cell-based assays for pharmacological characterization and behavioral tests in the BALB/cByJ mouse model of ASD-like social deficits.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  4. 04AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome

    In the BALB/cByJ mouse model, the synthetic oxytocin receptor agonist TC-OT-39 had no prosocial efficacy.

    In plain wordsIn mice with autism-like social deficits, the oxytocin-like drug TC-OT-39 did not improve social behaviour.

    Peptide
    Oxytocin
    Outcome
    No significant changeProsocial efficacy of TC-OT-39
    Study

    mousen: not reported in source

    BALB/cByJ mouse model of ASD-like social deficits
    Outcome group
    Social behavior and cognition · Nervous system and cognition

    Source sentences

    Summary
    neither synthetic agonist had prosocial efficacy in the BALB/cByJ model.
    1 context sentence
    Summary · context
    We first investigated two synthetic oxytocin analogs, TC-OT-39 and carbetocin, using in vitro cell-based assays for pharmacological characterization and behavioral tests in the BALB/cByJ mouse model of ASD-like social deficits.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  5. 05AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome

    In the BALB/cByJ mouse model, the synthetic oxytocin receptor agonist carbetocin had no prosocial efficacy.

    In plain wordsIn mice with autism-like social deficits, the oxytocin-like drug carbetocin did not improve social behaviour.

    Peptide
    Oxytocin
    Outcome
    No significant changeProsocial efficacy of carbetocin
    Study

    mousen: not reported in source

    BALB/cByJ mouse model of ASD-like social deficits
    Outcome group
    Social behavior and cognition · Nervous system and cognition

    Source sentences

    Summary
    neither synthetic agonist had prosocial efficacy in the BALB/cByJ model.
    1 context sentence
    Summary · context
    We first investigated two synthetic oxytocin analogs, TC-OT-39 and carbetocin, using in vitro cell-based assays for pharmacological characterization and behavioral tests in the BALB/cByJ mouse model of ASD-like social deficits.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  6. 06LabNot a test of Oxytocin aloneIn vitro (cells)Activity measurement

    In cell-based assays, the synthetic analogs TC-OT-39 and carbetocin both selectively activated the oxytocin receptor.

    In plain wordsIn cells, the oxytocin-like drugs TC-OT-39 and carbetocin both selectively switched on the oxytocin receptor.

    Peptide
    Oxytocin
    Outcome
    Not applicableOXTR activation by TC-OT-39 and carbetocin
    Study

    n: not reported in source

    In vitro cell-based assays
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    both TC-OT-39 and carbetocin selectively activate the OXTR
    1 context sentence
    Summary · context
    using in vitro cell-based assays for pharmacological characterization

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.